Related references
Note: Only part of the references are listed.Cannabis Use and Prospective Long-Term Association with Anxiety: A Systematic Review and Meta-Analysis of Longitudinal Studies: Usage du cannabis et association prospective a long terme avec l'anxiete: une revue systematique et une meta-analyse d'etudes longitudinales
Siqi Xue et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2021)
Acute effects of cannabinoids on addiction endophenotypes are moderated by genes encoding the CB1 receptor and FAAH enzyme
Chandni Hindocha et al.
ADDICTION BIOLOGY (2020)
Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease
Stephanie Martins de Faria et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2020)
Use of cannabidiol in anxiety and anxiety-related disorders
Jessica W. Skelley et al.
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2020)
Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance A Randomized Clinical Trial
Thomas R. Arkell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
New trends in cannabis potency in USA and Europe during the last decade (2008-2017)
Suman Chandra et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2019)
Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition
Thomas R. Arkell et al.
PSYCHOPHARMACOLOGY (2019)
How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review
Abigail M. Freeman et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2019)
Δ-9-Tetrahydrocannabinol and Cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors
Hanna J. Szkudlarek et al.
NEUROPSYCHOPHARMACOLOGY (2019)
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
Ila M. Linares et al.
BRAZILIAN JOURNAL OF PSYCHIATRY (2019)
Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation
N. Krcevski-Skvarc et al.
EUROPEAN JOURNAL OF PAIN (2018)
Trends in and correlates of medical marijuana use among adults in the United States
Beth Han et al.
DRUG AND ALCOHOL DEPENDENCE (2018)
Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal
Richard C. Kevin et al.
FORENSIC TOXICOLOGY (2017)
Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats
Erin M. Rock et al.
PSYCHOPHARMACOLOGY (2017)
Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life
Antonio W. Zuardi et al.
Frontiers in Pharmacology (2017)
Chronic Adolescent Δ9-Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment
Michelle Murphy et al.
CANNABIS AND CANNABINOID RESEARCH (2017)
Neural correlates of interactions between cannabidiol and (9)-tetrahydrocannabinol in mice: implications for medical cannabis
S. M. Todd et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Evaluating the public health impacts of legalizing recreational cannabis use in the United States
Wayne Hall et al.
ADDICTION (2016)
The Emotional Stroop Task: Assessing Cognitive Performance under Exposure to Emotional Content
Moshe Shay Ben-Haim et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2016)
Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
R. B. Laprairie et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
The endocannabinoid system in guarding against fear, anxiety and stress
Beat Lutz et al.
NATURE REVIEWS NEUROSCIENCE (2015)
Cannabidiol as a Potential Treatment for Anxiety Disorders
Esther M. Blessing et al.
NEUROTHERAPEUTICS (2015)
Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability
Fabio Arturo Iannotti et al.
ACS CHEMICAL NEUROSCIENCE (2014)
Therapeutic potential of cannabinoid medicines
P. J. Robson
DRUG TESTING AND ANALYSIS (2014)
Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis
Yahiya Y. Syed et al.
DRUGS (2014)
Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial
Claudine C. Hunault et al.
PSYCHOPHARMACOLOGY (2014)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Differential role of CB1 and TRPV1 receptors on anandamide modulation of defensive responses induced by nitric oxide in the dorsolateral periaqueductal gray
S. F. Lisboa et al.
NEUROPHARMACOLOGY (2012)
Interaction between cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids
Antonio Waldo Zuardi et al.
PSYCHOPHARMACOLOGY (2012)
Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry
David M. Schwope et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2011)
Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration
E. L. Karschner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential
Andreas M. Stadelmann et al.
NEUROSCIENCE LETTERS (2011)
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain
Jeremy R. Johnson et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2010)
Δ9-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus
Nora Laaris et al.
NEUROPHARMACOLOGY (2010)
Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology
Sagnik Bhattacharyya et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression
Fabricio A. Moreira et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond
Roger G. Pertwee
ADDICTION BIOLOGY (2008)
Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system
Mohammad-Reza Zarrindast et al.
BEHAVIOURAL PHARMACOLOGY (2008)
Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism
Kazuhide Hayakawa et al.
BRAIN RESEARCH (2008)
CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour
T. Rubino et al.
NEUROPHARMACOLOGY (2008)
Sativex®:: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
MP Barnes
EXPERT OPINION ON PHARMACOTHERAPY (2006)
New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis
A Ligresti et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
A role for cannabinoid CB1 receptors in mood and anxiety disorders
JM Witkin et al.
BEHAVIOURAL PHARMACOLOGY (2005)
Effects of cannabidiol (CBD) on regional cerebral blood flow
JAD Crippa et al.
NEUROPSYCHOPHARMACOLOGY (2004)
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis
DC D'Souza et al.
NEUROPSYCHOPHARMACOLOGY (2004)
Cannabis use and mental health in young people: cohort study
GC Patton et al.
BMJ-BRITISH MEDICAL JOURNAL (2002)
Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users
HV Curran et al.
PSYCHOPHARMACOLOGY (2002)
Share Paper
